Risk of Acne in Patients With Atopic Dermatitis Starting a JAK Inhibitor vs Th2 Cytokine Inhibitor

Maria C. Schneeweiss, Dermato-Pharmacoepidemiology Program, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Richard Wyss, Dermato-Pharmacoepidemiology Program, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Priyanka Anand, Dermato-Pharmacoepidemiology Program, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Yinzhu Jin, Dermato-Pharmacoepidemiology Program, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Arash Mostaghimi, Harvard Medical School, Boston, Massachusetts.
John Barbieri, Harvard Medical School, Boston, Massachusetts.
Joseph F. Merola, Division of Rheumatology, Department of Dermatology and Department of Medicine, UT Southwestern Medical Center and O'Donnell School of Public Health, Dallas, Texas.
Jonathan I. Silverberg, Department of Dermatology, George Washington University, Washington, DC.
David M. Rosmarin, Department of Dermatology, Indiana University, Indianapolis.
Robert J. Glynn, Dermato-Pharmacoepidemiology Program, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Sebastian Schneeweiss, Dermato-Pharmacoepidemiology Program, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

Document Type

Journal Article

Publication Date

1-21-2026

Journal

JAMA dermatology

DOI

10.1001/jamadermatol.2025.5443

Department

Dermatology

Link to Full Text

Share

COinS